SS Innovations International (SSII) Furthers Market Penetration Strategy with 100th Cardiac Robotic Procedure

Surgical robotics company, SS Innovations International, Inc. (SSII) has announced a milestone for robotic cardiac surgery as its SSi Mantra Surgical Robotic System has surpassed its 100th cardiac surgery.

The company who is dedicated to making world class robotic surgery affordable and accessible, globally implements the world’s only comprehensive robotic cardiac surgery program. Additionally, its SSi Mantra has been used in over 1000 procedures, around the world.

According to ResearchAndMarkets, the global markets for both cardiac surgery devices and surgical robotics are valued at $17.1Bn and $78.8B, respectively. Both are also expected to grow over the next ten years at a mid-to-high single digit compound annual growth rate.

Dr. Sudhir Srivastava, SS Innovation’s Chairman and CEO stated, “Our approach enables the same surgeries to be performed with minimal invasiveness, exemplifying the SSi Mantra system’s unique value proposition: precise execution, less trauma, reduced blood loss, quicker recoveries, lower cost and superior overall outcomes. We anticipate receiving FDA approval in the US and CE Mark approval in Europe in early 2025, further enhancing our market position.” 

About SS Innovations International, Inc.

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at or LinkedIn for updates.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

SS Innovations International (SSII) Furthers Market Penetration Strategy with 100th Cardiac Robotic Procedure

Ashlee Vogenthaler

Markets Editor